# Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

> **NCT05048901** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 49 (estimated)

## Conditions studied

- Neuroendocrine Tumors,Gastroenteropancreatic

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT05048901
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-17
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048901, "Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05048901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*